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Protein incorporated later into tight junctions (Pilt), also termed tight junction-associated protein 1
or tight junction protein 4, is a coiled-coil domain-containing protein that was originally identiﬁed
as a human discs large-interacting protein. In this study, we identiﬁed Pilt as an Arf6-binding
protein by yeast two-hybrid screening. By immunocytochemical analysis, Pilt was shown to be pre-
dominantly localized at the trans-Golgi complex and to exhibit diffuse cytoplasmic distribution in
association with endosomes and plasma membrane in NIH3T3 cells. Silencing of endogenous Pilt
disrupted the Golgi structure. The present ﬁndings suggest the functional involvement of Pilt in
the maintenance of the Golgi structure.
Structured summary of protein interactions:
GM130 and Pilt colocalize by ﬂuorescence microscopy (View interaction)
Arf6(Q67L) physically interacts with Pilt by two hybrid (View Interaction: 1, 2)
Pilt physically interacts with Arf6(Q67L) by pull down (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Class III (Arf6) on the basis of the structural similarity. Five Arfs,The Golgi complex is a morphologically complicated intracellu-
lar organelle consisting of a stack of ﬂattened membrane-enclosed
cisternae. Despite constant ﬂow of membrane and cargo, the Golgi
complex maintains its highly organized structure. An increasing
number of molecules that regulate the Golgi structure have re-
cently been identiﬁed, including Golgi matrix proteins, small
GTPases, lipid-modifying enzymes, protein kinases, motor proteins
and cytoskeletal proteins. Among Golgi matrix proteins, golgins are
a family of coiled-coil domain-containing proteins that localize
preferentially at the Golgi. They regulate the membrane trafﬁcking
and structural organization of the Golgi through interaction with
various small GTPases including ADP ribosylation factors (Arfs),
Arf-like factors (Arls) and Rabs [1–3].
Arfs are key regulators of membrane trafﬁcking and actin cyto-
skeleton dynamics [4–6]. There are six Arf proteins that can be di-
vided into Class I (Arf1, Arf2 and Arf3), Class II (Arf4 and Arf5) andchemical Societies. Published by E
Arf-like factor; GFP, green
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-Golgi network; TJAP, tight
. Sakagami).excluding Arf6, localize and function at the Golgi. Experiments
using RNA interference showed that double but not single
knockdown of Class I and II Arfs disturbs the Golgi morphology
and various steps of Golgi transport, indicating that they coopera-
tively function in the Golgi [7]. On the other hand, Arf6, the most
structurally divergent member, localizes at the plasma membrane
and endosomes and regulates actin cytoskeleton dynamics and
membrane trafﬁcking in and out of the plasma membrane. Since
the biological actions of Arfs are thought to result from their
speciﬁc interaction with effectors, it is crucial to identify novel
effectors to understand the molecular mechanisms behind
Arf-mediated biological processes.
During our attempt to identify neuronal Arf6 effectors, we pre-
viously identiﬁed vezatin and demonstrated its functional involve-
ment in dendritic formation in cultured hippocampal neurons [8].
In this study, we identiﬁed Protein incorporated later into tight
junctions (Pilt) as an Arf6-binding protein by additional yeast
two-hybrid screening. Pilt, also termed tight junction-associated
protein 1 (TJAP1) or tight junction protein 4, was originally isolated
as a human discs large (hDlg)-binding protein by yeast two-hybrid
screening [9]. Although Pilt was previously shown to localize at
tight junctions and some intracellular organelles, the physiological
roles of Pilt remain unknown. We demonstrated the predominantlsevier B.V. All rights reserved.
H. Tamaki et al. / FEBS Letters 586 (2012) 3064–3070 3065localization of Pilt at the trans-Golgi complex and its functional
involvement in the maintenance of the Golgi structure in NIH3T3
cells.
2. Materials and methods
2.1. DNA construct
Two-hybrid bait vectors for Arf mutants were described previ-
ously [8]. A mammalian expression vector for N-terminally
c-Myc epitope-tagged Pilt, pCMV-Myc-Pilt(1–549), was created
by digesting clone 125 in pPC86 with SalI and NotI and subcloning
the insert into pCMV-Myc (Clontech Laboratories, Mountain View,
CA, USA). Truncated mutants of Pilt shown in Figs. 1 and 4A wereFig. 1. Interaction of Pilt with GTP-bound ARF6. (A) Schematic representation of the clon
with Arf6. Note the presence of a 10-amino acid insertion in clone 125 compared with th
amino acid sequences between clone 125 and TJAP1 (accession number NM_028751). N
sites. The nucleotide and amino acid sequences inserted into clone 125 are shown in the b
accession number AB712252. (C, D) Yeast two hybrid assays to determine the speciﬁci
interaction with Arf6 (D). Yeast co-transformed with the indicated combination of plasm
b-galactosidase assay (b-gal) and plated onto medium lacking leucine, tryptophan, histid
an N-terminal region corresponding to amino acids 1–285. (E) Pull down assay. The lysa
pull down assay with GST-Pilt, GST-GGA1 or GST. The precipitates and lysate were immuampliﬁed by PCR with primers (Supplementary Table 1) and sub-
cloned into pPC86 (Invitrogen, Carlsbad, CA, USA) or pCMV-Myc
(Clontech) in frame. Mammalian expression vectors for C-termi-
nally hemagglutinin (HA) epitope-tagged Arfs (Arfs-HA) and a bac-
terial expression vector for the glutathione S-transferase (GST)
fusion protein of Golgi-localized, c-ear-containing Arf-binding pro-
tein 1 (GGA1) were kindly provided by Dr. Kazuhisa Nakayama
(Kyoto University). A bacterial expression vector for Pilt was cre-
ated by subcloning the insert of clone 125 into pGEX4T-2 (GE
Healthcare, Piscataway, NJ, USA). For the antibody production,
the C-terminal region of Pilt (amino acids 191–549) was ampliﬁed
by PCR with the primers (Supplementary Table 1) and subcloned
into pGEX4T-2 and modiﬁed pMAL-2c vectors (New England
Biolabs, Beverly, MA, USA) [8]. For the RNA interference assay,e 125 and Pilt mutants used to determine the region responsible for the interaction
e amino acid sequence of TJAP1, a mouse orthologue of human Pilt. (B) Alignment of
ucleotide numbers on the left indicate the positions from the translation initiation
ox. The sequence of clone 125 has been deposited at DDBJ/EMBL/GenBank under the
ty of the interaction of Pilt with Arf6 (C) and the region of Pilt responsible for the
ids were grown on medium lacking leucine and tryptophan (LT()) and subjected to
ine and uracil (LTHU()). Note that Pilt can interact speciﬁcally with Arf6(Q67L) via
tes of COS-7 cells transfected with the indicated Arf6-HA vectors were subjected to
noblotted with an anti-HA antibody. Note the ability of Pilt to bind GTP-bound Arf6.
Fig. 2. Tissue distribution of Pilt by immunoblot analysis, The lysates of various adult mouse tissues (10 lg) and COS-7 cells transfected with pCMV-Myc-Pilt (1–549) were
immunoblotted with anti-Pilt or anti-c-Myc antibodies.
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region or oligonucleotides with four mutations in the target se-
quence (sh-Pilt(mut)) (Supplementary Table 1) were annealed
and subcloned into modiﬁed mU6pro vectors that can express Ve-
nus under the cytomegalovirus promoter [8]. The mU6pro-Venus
vector for ﬁreﬂy luciferase (sh-Luc) was described previously [8].
2.2. Yeast two-hybrid assay
Approximately 6  106 clones of a mouse brain cDNA library
were screened using a yeast two-hybrid system (ProQuest Two-
Hybrid system, Invitrogen) with Arf6(Q67L) as bait as described
previously [8].
2.3. Pull down assay
The lysates of COS-7 cells expressing Arf6(Q67L)-HA,
Arf6(T44N)-HA or wild-type Arf6-HA were subjected to pull down
assay using GST alone, GST-Pilt(1–549) or GST-GGA1 immobilized
on glutathione Sepharose 4B (GE Healthcare) as described previ-
ously [8]. In the case of wild-type Arf6-HA, the lysates were incu-
bated with 200 lM GTPcS or 1 mM GDP before the pull down
assay.
2.4. Antibody
A polyclonal guinea pig anti-Pilt antibody was prepared by
immunizing a guinea pig ﬁve times with GST-Pilt(191–549). The
speciﬁc antibody was afﬁnity-puriﬁed using CNBr-activated Se-
pharose 4B (GE Healthcare) coupled with Pilt(191–549) fused to
maltose-binding protein.
2.5. Western blot analysis
Various tissues from adult mice were homogenized with 10 vol-
umes of lysis buffer (250 mM Tris–HCl (6.8), 4% SDS, 20% glycerol
and 10% 2-mercaptoethanol) and boiled for 5 min. The lysates of
tissues (10 lg) and COS-7 cells transfected with pCMV-Myc-
Pilt(1–549) were subjected to immunoblot analysis with antibod-
ies against Pilt (0.1 lg/ml) or c-Myc (Santa Cruz Biotechnology,
Santa Cruz, CA, USA).
2.6. Immunocytochemistry
NIH3T3 cells were ﬁxed with 4% paraformaldehyde and sub-
jected to triple immunoﬂuorescent staining with guinea pig anti-Pilt IgG (1 lg/ml), rabbit anti-GM130 serum (1:2000, product
#PM061, MBL, Nagoya, Japan) and mouse anti-TGN38 IgG (1 lg/
ml, product #610898, BD Transduction Laboratories, San Diego,
CA, USA). Immunoﬂuorescent images were taken with a confocal
laser scanning microscope (LSM 710, Carl Zeiss, Jena, Germany).
For pre-embedding immunoelectron microscopy, NIH3T3 cells
were incubated with anti-Pilt IgG overnight, followed by two-hour
incubation with nanogold-conjugated anti-guinea pig IgG (1:100,
Nanoprobes, Yaphank, NY, USA). The immunoreaction was en-
hanced using a HQ Silver Enhancement kit (Nanoprobes). The cells
were post-ﬁxed with 1% osmium tetroxide, stained with 2% uranyl
acetate, dehydrated and embedded in epoxy resin. Ultrathin sec-
tions were observed using an electron microscope (H7650,
Hitachi).
To determine the region responsible for the Golgi targeting,
HeLa cells were transfected with c-Myc-Pilt mutants (0.5 lg/
35 mm-dish) using Lipofectamine 2000 (Invitrogen). They were
ﬁxed at 18–20 h after transfection and subjected to immunostain-
ing with antibodies against c-Myc and GM130.
2.7. Short hairpin RNA (shRNA)-mediated knockdown of Pilt
To evaluate the efﬁciency of shRNA vectors, COS-7 cells were
co-transfected with pCMV-Myc-Pilt(1–549) and shRNA vectors
and subjected to immunoblot analysis with antibodies against c-
Myc, b-actin (Sigma–Aldrich, Saint Louis, MO, USA) and green ﬂuo-
rescent protein (GFP). To examine the Golgi morphology, NIH3T3
cells were transfected with shRNA vectors (3 lg/35 mm-dish) for
3 days and subjected to immunostaining with antibodies against
GM130, GFP and Pilt. We observed a total of 100–150 cells express-
ing GFP from three independent experiments in a blind manner
and divided the morphology of the Golgi into normal or frag-
mented types. The Golgi was judged as fragmented when the
immunoﬂuorescence for GM130 exhibited punctate membranous
structures or dispersed proﬁles rather than perinuclear tubular
structures. For electron microscopic observation, transfected cells
identiﬁed by GFP ﬂuorescence before ﬁxation were subjected to
electron microscopy.
3. Results
3.1. Isolation of Pilt as a GTP-bound Arf6-binding protein by yeast two-
hybrid screening
To identify a novel Arf6-interacting protein, we have previously
screened a mouse brain DNA library with a GTPase-defective Arf6
Fig. 3. Predominant localization of Pilt at the Golgi complex. (A–E) Immunoﬂuores-
cent localization of Pilt in NIH3T3 cells. NIH3T3 cells were immunostained with
antibodies against Pilt (A, B, green), TGN38 (C, red) and GM130 (D, blue). Note the
more overlapped localization of Pilt with TGN than GM130. Note also the ﬁne
immunoﬂuorescent signals throughout the cytoplasm and beneath the plasma
membrane. (F, G) Immunoelectronmicrographs. The region boxed in (F) ismagniﬁed
in (G). Note the preferential localization of Pilt at the trans-Golgi complex. Note also
the distribution of Pilt throughout the cytoplasm in association with membranous
structures. Scale bars, 10 lm in (A); 1 lm in (E) and (F); 500 nm in (G).
Fig. 4. The region of Pilt required for the Golgi targeting. (A) The schematic
representation of Pilt mutants. (B) Localization of transfected Pilt mutants in HeLa
cells. HeLa cells were transfected with the indicated c-Myc-Pilt mutants and
subjected to immunostaining with anti-c-Myc and anti-GM130 antibodies. Note the
requirement of the central region (amino acids 311–439) for the Golgi targeting.
H. Tamaki et al. / FEBS Letters 586 (2012) 3064–3070 3067mutant, Arf6(Q67L), as bait [8]. By additional screening, we iso-
lated a cDNA (clone 125) encoding a mouse orthologue of humanPilt, which was originally identiﬁed as an hDlg-interacting protein
[9]. Sequencing analysis revealed that clone 125 contained an en-
tire coding region that was identical to that of a cDNA clone depos-
ited as TJAP1 in GenBank (NM_028751), except for an insertion of
30 nucleotides (Fig. 1A and B). As a result, it encodes a protein of
3068 H. Tamaki et al. / FEBS Letters 586 (2012) 3064–3070549 amino acids with a predicted molecular weight of 61 kDa.
Since the insertion was placed at the splicing site on the basis of
its genomic sequence, the clone 125 is likely to encode an alterna-
tive splice variant.
To examine whether Pilt could interact promiscuously with
other Arf proteins, the yeast strain MaV203 was co-transformed
with Pilt and various Arf mutants and subjected to b-galactosidase
assay (Fig. 1C). Only the yeast clone co-transformed with Pilt and
Arf6(Q67L) exhibited high b-galactosidase activity and the ability
to grow without uracil, suggesting the speciﬁc interaction of Pilt
with GTP-Arf6 among the Arf family.
We further determined the domain of Pilt responsible for the
interaction with Arf6 by b-galactosidase assay with truncated mu-
tants shown in Fig. 1A. The yeast clones expressing Pilt(1–549) and
Pilt(1–285) together with Arf6(Q67L) exhibited high b-galactosi-
dase activity and prototrophy for uracile (Fig. 1D). On the other
hand, the yeast clones expressing Pilt(1–175) or Pilt(176–549)
did not exhibit any apparent b-galactosidase activity or prototro-
phy for uracile. These ﬁndings suggest that the N-terminal region
of Pilt containing a coiled-coil domain and adjacent sequences is
required for the interaction with Arf6(Q67L).
Finally, we examined the interaction between Pilt and Arf6 by
an independent assay. An in vitro GST pull down assay demon-
strated that GST-Pilt(1–549) efﬁciently pulled down Arf6(Q67L)-
HA and wild-type Arf6-HA incubated with GTPcS, but not
Arf6(T44N)-HA, a GDP-locked mutant (Fig. 1E). In the control
experiment, GGA1-GST but not GST efﬁciently pulled down Arf6-
HA incubated with GTPcS as described previously [10]. All these
ﬁndings suggest that Pilt can speciﬁcally interact with GTP-bound
Arf6.
3.2. Tissue distribution of Pilt
Tissue distribution of Pilt was examined by immunoblot analy-
sis (Fig. 2). The antibody reacted with a single band of 80 kDa, a
size identical to cMyc-Pilt(1–549), in various tissues including
the embryonic brain, thymus, heart, lung, liver, small intestine,
kidney, spleen, testis and skeletal muscle. Although Pilt was iso-
lated from an adult mouse brain cDNA library, the antibody failed
to detect Pilt in the adult brain. An additional immunoreactive
band of 60 kDa was detected in the liver and kidney, suggesting
the existence of an alternative splice variant or closely related
molecule.
3.3. Subcellular localization of Pilt
Immunoﬂuorescent analysis revealed prominent juxtanuclear
immunolabeling in NIH3T3 cells (Fig. 3A). Triple immunostaining
with cis/medial- (GM130) and trans-Golgi (TGN38) markers re-
vealed that Pilt overlapped completely with TGN38 but partially
with GM130 (Fig. 3B–E). In addition, faint but distinct immunoﬂu-
orescence for Pilt was distributed throughout the cytoplasm and
beneath the plasma membrane (Fig. 3A). The preferential localiza-
tion of Pilt at the trans-Golgi was further conﬁrmed by experi-
ments with brefeldin A (BFA). As early as 5 min after the addition
of BFA, mannosidase II, a cis/medial Golgi marker, was redistrib-
uted to a ﬁne reticular pattern and scattered throughout the cyto-
plasm, while Pilt still remained to be juxtanuclear in association
with TGN38 (Supplementary Fig. 1). The predominant localization
of Pilt at the Golgi complex was also true for other cell types
including HeLa cells, intestinal absorptive cells, epididymal epithe-
lial cells and adrenal chromafﬁn cells (Supplementary Fig. 2). It is
noteworthy that this antibody did not label junctional complexes
in intestinal absorptive cells, epididymal epithelial cells (Supple-
mentary Fig. 2) or Madin-Darby canine kidney (MDCK) cells
(Supplementary Fig. 3).We further performed pre-embedding immunogold electron
microscopy (Fig. 3F and G). In NIH3T3 cells, immunogold particles
were accumulated most densely on the concave trans face of the
Golgi stacks and on tubulovesicular structures of the trans-Golgi
network (TGN) without immunoreaction on the cis face (Fig. 3G).
Immunogold particles were also distributed throughout the cyto-
plasm in close association with small vesicles, presumably endo-
somes, and beneath the plasma membrane (Fig. 3F). In contrast,
nuclei and mitochondria were rarely immunolabeled. All these
ﬁndings suggest the occurrence of Pilt at the trans-Golgi complex,
endosomes and plasma membrane.
3.4. The region of Pilt required for the targeting to the Golgi complex
To determine the region of Pilt responsible for the Golgi tar-
geting, the localizations of various Pilt mutants transfected in
COS-7 cells were examined by immunostaining with antibodies
against c-Myc and GM130 (Fig. 4). When c-Myc-Pilt(1–549) was
expressed at a low level, it was closely associated with GM130
as described for endogenous Pilt (Fig. 4B). However, when ex-
pressed at moderate to high levels, it exhibited predominant
cytoplasmic distribution that masked underlying structures, sug-
gesting the Golgi localization of Pilt in a saturable manner. When
expressed at a weak level, c-Myc-Pilt(176–549) was efﬁciently
targeted to the Golgi, while c-Myc-Pilt(1–175) failed to be tar-
geted to the Golgi and was distributed as aggregates unrelated
to GM130 (Fig. 4B). Further deletion revealed that c-Myc-
Pilt(176–439), (176–439), (311–549) and (311–439) exhibited
perinuclear Golgi patterns (Fig. 4B). Therefore, the C-terminal
two-thirds, particularly a central region corresponding to amino
acids 311–439, are suggested to be important for the Golgi
localization.
3.5. Disruption of the Golgi structure by silencing endogenous Pilt
The efﬁciency of shRNA vector for Pilt was evaluated by immu-
noblot analysis using the lysates of COS-7 cells co-transfected with
c-Myc-Pilt and shRNA vectors. Exogenously expressed c-Myc-Pilt
was efﬁciently attenuated by co-transfection with sh-Pilt but not
with sh-Luc or sh-Pilt(mut) (Fig. 5A). Furthermore, endogenous Pilt
was efﬁciently depleted in approximately 80% of NIH3T3 cells
transfected with sh-Pilt (Fig. 5B).
We ﬁnally examined the effect of silencing of endogenous Pilt
on the morphology of the Golgi in NIH3T3 cells. When transfected
with sh-Pilt(mut) or sh-Luc, cells exhibited juxtanuclear crescent-
shaped, ring-like or large punctate immunoﬂuorescent patterns
for GM130, which were indistinguishable from those in naïve
NIH3T3 cells. In striking contrast, the immunoﬂuorescence for
GM130 was dispersed as numerous vesicular structures in 51.6%
of cells transfected with sh-Pilt (Fig. 5B, C). Transfection of sh-Pilt
did not apparently disturb cell survival or mitosis (data not
shown). At the electron microscopic level, NIH3T3 cells expressing
sh-Luc or sh-Pilt (mut) had typical Golgi complexes with stacks
consisting of multiple elongated ﬂat cisternae. In contrast, cells
expressing sh-Pilt exhibited more tubulovesicular structures and
many fragmented small Golgi stacks with individual cisternae
being slightly dilated (Fig. 5D). Taken together, these ﬁndings sug-
gest the functional involvement of Pilt in the maintenance of the
Golgi structure.4. Discussion
Pilt is a coiled-coil domain-containing protein that was origi-
nally identiﬁed as an hDlg-binding protein by yeast two-hybrid
screening [9]. Pilt was named after its molecular feature that this
Fig. 5. Disruption of the Golgi structure by silencing endogenous Pilt in NIH3T3 cells. (A) Immunoblot analysis. COS-7 cells were transfected with sh-Pilt or sh-Pilt(mut)
vectors with c-Myc-Pilt and subjected to immunoblot analysis with antibodies against c-Myc, b-actin and GFP. Note the attenuation of c-Myc-Pilt by co-expression of sh-Pilt
but not sh-Pilt(mut). (B) Immunoﬂuorescent analysis. NIH3T3 cells were transfected with sh-Pilt or sh-Pilt(mut) and subjected to immunostaining with antibodies against
GFP, Pilt and GM130. Note the decrease of endogenous Pilt by expression of sh-Pilt but not sh-Pilt(mut). Note also the dispersed immunoﬂuorescence for GM130 in cells
transfected with sh-Pilt (arrows). (C) Quantiﬁcation of the effect of silencing of Pilt on the Golgi fragmentation from three independent experiments. Data are mean ± S.D.
⁄P < 0.005, Student’s t-test. (D) Representative electron micrographs showing the Golgi morphology in NIH3T3 cells expressing sh-Pilt or sh-Pilt(mut). Arrows indicate
fragmented mini-Golgi stacks with slightly swollen cisternae. Scale bars, 1 lm.
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the wound-healing process. However, physiological functions of
Pilt were completely unknown. In this study, we isolated Pilt
as an Arf6-interacting protein by yeast two hybrid screening.
Although the functional signiﬁcance of the interaction between
Arf6 and Pilt is still unknown, we demonstrated the predomi-
nant localization of Pilt at the Golgi complex and its functional
signiﬁcance in the maintenance of the Golgi structure.
The yeast two-hybrid and pull down assays independently
demonstrated the speciﬁc interaction of Pilt with GTP-bound
Arf6. However, a discrepancy of major subcellular locations be-
tween Pilt and Arf6 is puzzling. Exogenously expressed Arf6 was
reported to localize mainly at the plasma membrane and endo-
somes, but not at the Golgi [11,12]. Therefore, the Golgi complex
is unlikely to be the place where the interaction between Pilt and
Arf6 takes place in vivo. Although Pilt localizes predominantly at
the Golgi in a steady state, it is also found in the cytoplasm in asso-
ciation with endosomes and the plasma membrane, suggesting
that Pilt may cycle between the plasma membrane and TGN via
endosomes. Thus, it is still possible that Pilt may interact with
Arf6 in vivo at endosomes or the plasma membrane. Further
studies are necessary to elucidate the physiological relationship
between ARF6 and Pilt.Pilt exhibits a polarized localization to the trans-Golgi com-
plex as revealed by immunocytochemical analysis at both light
and electron microscopic levels. In view of the presence of a
coiled-coil domain and the predominant localization at the Gol-
gi, Pilt might be categorized as a novel member of the golgin
family. We further demonstrated that the C-terminal two-thirds,
particularly a central region (amino acids 311–439), is impor-
tant for the Golgi localization, while the N-terminal region
(amino acids 1–285) containing a coiled-coil domain is required
for the interaction with Arf6, suggesting that Pilt is targeted to
the Golgi independently of Arf6. Since exogenously expressed
Pilt localizes at the Golgi in a saturable manner, it is reasonable
to consider that Pilt is targeted to the Golgi through the inter-
action of its central region with some other Golgi-associated
protein(s). Identiﬁcation of Pilt-interacting proteins is currently
under way in our laboratory to understand its Golgi targeting
mechanism.
In contrast to a previous ﬁnding [9], the present anti-Pilt anti-
body failed to label tight junctions in various cell types. This dis-
crepancy may stem from the differences in the sensitivity and
speciﬁcity between the previous and present antibodies, which
were raised against the N-terminal half [9] and the C-terminal
two-thirds, respectively. Since both antibodies can label similar
3070 H. Tamaki et al. / FEBS Letters 586 (2012) 3064–3070intracellular structures except tight junctions, the expression of
Pilt at tight junctions may be below the level of detectability
of our antibody. Alternatively, the conformation or complex for-
mation of Pilt may differ between tight junctions and the Golgi
complex and only the previous antibody could recognize Pilt at
tight junctions.
By silencing endogenous Pilt, we provided evidence for the
functional involvement of Pilt in the maintenance of the Golgi
structure. The Golgi structure is maintained by various compo-
nents that regulate membrane trafﬁcking into and out of the Golgi,
the interaction between Golgi and microtubules, and cisternal
stacking [2]. Among these features, there is a precedent for
TGN-localized proteins with coiled-coil domains, TGN golgins,
inﬂuencing the Golgi structure [1,13–15]. Further studies are nec-
essary to examine whether Pilt maintains the structural integrity
of the Golgi by regulating the dynamics of the cytoskeleton and/
or membrane trafﬁcking at the TGN.Acknowledgements
We thank Dr. Kazuhisa Nakayama (Kyoto University) for
vectors for Arfs-HA and GST-GGA1 and Dr. David L. Turner
(University of Michigan) for mU6pro vector. This work was sup-
ported by Grants-in-Aid for Scientiﬁc Research to H.S. (#2165049
and #22300114) from the Ministry of Education, Science, Sports,
Culture, and Technology of Japan and grants from Kitasato
University.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2012.
07.051.References
[1] Derby, M.C., Lieu, Z.Z., Brown, D., Stow, J.L., Goud, B. and Gleeson, P.A. (2007)
The trans-Golgi network golgin, GCC185, is required for endosome-to-Golgi
transport and maintenance of Golgi structure. Trafﬁc 8, 758–773.
[2] Short, B., Haas, A. and Barr, F.A. (2005) Golgins and GTPases, giving identity
and structure to the Golgi apparatus. Biochim. Biophys. Acta 1744, 383–395.
[3] Barr, F.A. and Short, B. (2003) Golgins in the structure and dynamics of the
Golgi apparatus. Curr. Opin. Cell Biol. 15, 405–413.
[4] D’Souza-Schorey, C. and Chavrier, P. (2006) ARF proteins: roles in membrane
trafﬁc and beyond. Nat. Rev. Mol. Cell Biol. 7, 347–358.
[5] Donaldson, J.G. and Jackson, C.L. (2011) ARF family G proteins and their
regulators: roles in membrane transport, development and disease. Nat. Rev.
Mol. Cell Biol. 12, 362–375.
[6] Gillingham, A.K. and Munro, S. (2007) The small G proteins of the Arf family
and their regulators. Annu. Rev. Cell Dev. Biol. 23, 579–611.
[7] Volpicelli-Daley, L.A., Li, Y., Zhang, C.J. and Kahn, R.A. (2005) Isoform-selective
effects of the depletion of ADP-ribosylation factors 1–5 on membrane trafﬁc.
Mol. Biol. Cell 16, 4495–4508.
[8] Sanda, M. et al. (2010) Vezatin, a potential target for ADP-ribosylation factor 6,
regulates the dendritic formation of hippocampal neurons. Neurosci. Res. 67,
126–136.
[9] Kawabe, H., Nakanishi, H., Asada, M., Fukuhara, A., Morimoto, K., Takeuchi, M.
and Takai, Y. (2001) Pilt, a novel peripheral membrane protein at tight
junctions in epithelial cells. J. Biol. Chem. 276, 48350–48355.
[10] Takatsu, H., Yoshino, K., Toda, K. and Nakayama, K. (2002) GGA proteins
associate with Golgi membranes through interaction between their GGAH
domains and ADP-ribosylation factors. Biochem. J. 365, 369–378.
[11] D’Souza-Schorey, C., van Donselaar, E., Hsu, V.W., Yang, C., Stahl, P.D. and
Peters, P.J. (1998) ARF6 targets recycling vesicles to the plasma membrane:
insights from an ultrastructural investigation. J. Cell Biol. 140, 603–616.
[12] Peters, P.J., Hsu, V.W., Ooi, C.E., Finazzi, D., Teal, S.B., Oorschot, V., Donaldson,
J.G. and Klausner, R.D. (1995) Overexpression of wild-type and mutant ARF1
and ARF6: distinct perturbations of nonoverlapping membrane
compartments. J. Cell Biol. 128, 1003–1017.
[13] Goud, B. and Gleeson, P.A. (2010) TGN golgins, Rabs and cytoskeleton:
regulating the Golgi trafﬁcking highways. Trends Cell Biol. 20, 329–336.
[14] Yoshino, A. et al. (2005) TGolgin-1 (p230, golgin-245) modulates Shiga-toxin
transport to the Golgi and Golgi motility towards the microtubule-organizing
centre. J. Cell Sci. 118, 2279–2293.
[15] Lin, Y.C., Chiang, T.C., Liu, Y.T., Tsai, Y.T., Jang, L.T. and Lee, F.J. (2011) ARL4A
acts with GCC185 to modulate Golgi complex organization. J. Cell Sci. 124,
4014–4026.
